Evolution of the Average Target: Unicycive Therapeutics, Inc.

Evolution of the Target Price: Unicycive Therapeutics, Inc.

Changes in Analyst Recommendations: Unicycive Therapeutics, Inc.

17f381c475c5eed7d47c4.lPeiEtel3gBaIXm4bJo3xWXNYTA5Y1LGqfWNaz0O2to.36XXVbLIincAWS_CIKJj8TyjO0hLFWWEwJ3lKA0_r6vw2vtllNeVRwBNCg~e0c896c2a944daa0d4e698dfac1118c0
05-01 B. Riley Initiates Unicycive Therapeutics at Buy With $22 Price Target MT
11-12 Unicycive Therapeutics Q3 net loss widens to $6 mln RE
30/10/25 Unicycive Therapeutics, Inc. Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 CI
28/10/25 Unicycive Therapeutics, Inc. Provides Update from FDA Type A Meeting and Expects to Resubmit Olc Nda Before Year-End CI
21/04/25 Guggenheim Initiates Unicycive Therapeutics at Buy With $6 Price Target MT
06/09/24 Maxim Adjusts Price Target on Unicycive Therapeutics to $2 From $4, Maintains Buy Rating MT
04/04/24 Piper Sandler Initiates Coverage on Unicycive Therapeutics With Overweight Rating, $9 Price Target MT
16/08/23 HC Wainwright Adjusts Unicycive Therapeutics' Price Target to $4.50 From $7, Keeps Buy Rating MT
03/07/23 Roth MKM Adjusts Price Target on Unicycive Therapeutics to $4 From $5, Maintains Buy Rating MT
03/07/23 Maxim Adjusts Price Target on Unicycive Therapeutics to $4 From $6, Maintains Buy Rating MT
09/03/23 EF Hutton Starts Unicycive Therapeutics at Buy With $5 Price Target MT
09/03/23 Maxim Adjusts Price Target on Unicycive Therapeutics to $6 From $3, Maintains Buy Rating MT
28/11/22 HC Wainwright Cuts Price Target on Unicycive Therapeutics to $8 From $9, Keeps Buy Rating MT
08/06/22 HC Wainwright Starts Unicycive Therapeutics at Buy With $9 Price Target MT
16/03/22 Maxim Initiates Unicycive Therapeutics at Buy with $3 Price Target MT
17/08/21 UNICYCIVE THERAPEUTICS : Benchmark Starts Unicycive Therapeutics at Speculative Buy With $13 Price Target MT
09/08/21 UNICYCIVE THERAPEUTICS : Roth Capital Starts Unicycive Therapeutics at Buy With $13.50 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+637.77%
+8.88%
+19.1%
+30.09%
+76.66%
+23.66%
+26.94%
-21.65%
+4.61%
-9.85%
Average +79.62%
Weighted average by Cap. +19.36%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
5.360USD
Average target price
39.54USD
Spread / Average Target
+637.77%
High Price Target
90.00USD
Spread / Highest target
+1,579.10%
Low Price Target
13.00USD
Spread / Lowest Target
+142.54%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

B. Riley
Guggenheim
Piper Sandler
HC Wainwright
Roth MKM
Maxim
EF Hutton
Benchmark Capital
Roth Capital Partners
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
5.360USD
Average target price
39.54USD
Spread / Average Target
+637.77%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. UNCY Stock
  4. Consensus Unicycive Therapeutics, Inc.